Delayed-Action Preparations
"Delayed-Action Preparations" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Dosage forms of a drug that act over a period of time by controlled-release processes or technology.
| Descriptor ID |
D003692
|
| MeSH Number(s) |
D26.255.210 E02.319.300.253
|
| Concept/Terms |
Controlled-Release Preparations- Controlled-Release Preparations
- Controlled Release Preparations
- Controlled-Release Preparation
- Controlled-Release Formulations
- Controlled Release Formulations
- Controlled-Release Formulation
Sustained-Release Preparations- Sustained-Release Preparations
- Sustained-Release Preparation
- Extended Release Preparations
- Extended Release Preparation
- Slow Release Formulation
- Sustained Release Formulations
- Sustained Release Formulation
- Extended Release Formulations
- Extended Release Formulation
|
Below are MeSH descriptors whose meaning is more general than "Delayed-Action Preparations".
Below are MeSH descriptors whose meaning is more specific than "Delayed-Action Preparations".
This graph shows the total number of publications written about "Delayed-Action Preparations" by people in this website by year, and whether "Delayed-Action Preparations" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2007 | 1 | 2 | 3 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 1 | 2 | 3 |
| 2011 | 1 | 2 | 3 |
| 2012 | 0 | 1 | 1 |
| 2013 | 2 | 3 | 5 |
| 2014 | 1 | 3 | 4 |
| 2015 | 2 | 1 | 3 |
| 2016 | 0 | 5 | 5 |
| 2018 | 2 | 1 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Delayed-Action Preparations" by people in Profiles.
-
A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. Clin Pharmacol Ther. 2021 10; 110(4):1057-1065.
-
Sexually transmitted infections among women randomised to depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant. Sex Transm Infect. 2021 06; 97(4):249-255.
-
Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing Frequency. Clin Infect Dis. 2020 07 27; 71(3):517-524.
-
In situ thermo-co-electroresponsive mucogel for controlled release of bioactive agent. Int J Pharm. 2019 Mar 25; 559:255-270.
-
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018 11; 15(11):e1002690.
-
3D printed, controlled release, tritherapeutic tablet matrix for advanced anti-HIV-1 drug delivery. Eur J Pharm Biopharm. 2019 May; 138:99-110.
-
In Vitro-In Vivo Evaluation of an Oral Ghost Drug Delivery Device for the Delivery of Salmon Calcitonin. J Pharm Sci. 2018 06; 107(6):1605-1614.
-
Stimuli-Responsive Polymeric Systems for Controlled Protein and Peptide Delivery: Future Implications for Ocular Delivery. Molecules. 2016 Jul 30; 21(8).
-
A dual pH/Redox responsive copper-ligand nanoliposome bioactive complex for the treatment of chronic inflammation. Int J Pharm. 2016 Jul 25; 509(1-2):348-359.
-
Design of an In Situ Cross-Linked Eutectic Tablet for Enhanced Delivery of Gastro-Sensitive Proteins and Peptides. J Pharm Sci. 2016 07; 105(7):2086-98.